Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders

• Published in: International journal of molecular sciences Vol. 25; no. 6; p. 3203
• Main Authors: Ricardi, Caterina, Barachini, Serena, Consoli, Giorgio, Marazziti, Donatella, Polini, Beatrice, Chiellini, Grazia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2024; MDPI
• Subjects: Anxiety; Cognition disorders; COVID-19; depression; Development and progression; Diseases; Epidemics; Health aspects; inflammation; Kinases; Mental depression; Mental disorders; neuroinflammation; Neurophysiology; neuropsychiatric diseases; Review; COVID-19; anxiety; β-caryophyllene; cannabinoid type 2 receptor; inflammation; neuroinflammation; endocannabinoid system; depression; neuropsychiatric diseases
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25063203

Mental disorders account for one of the most prevalent categories of the burden of disease worldwide, with depression expected to be the largest contributor by 2030, closely followed by anxiety. The COVID-19 pandemic possibly exacerbated these challenges, especially amongst adolescents, who experienced isolation, disrupted routines, and limited healthcare access. Notably, the pandemic has been associated with long-term neurological effects known as "long-COVID", characterized by both cognitive and psychopathological symptoms. In general, psychiatric disorders, including those related to long-COVID, are supposed to be due to widespread inflammation leading to neuroinflammation. Recently, the endocannabinoid system (ECS) emerged as a potential target for addressing depression and anxiety pathophysiology. Specifically, natural or synthetic cannabinoids, able to selectively interact with cannabinoid type-2 receptor (CB2R), recently revealed new therapeutic potential in neuropsychiatric disorders with limited or absent psychotropic activity. Among the most promising natural CB2R ligands, the bicyclic sesquiterpene β-caryophyllene (BCP) has emerged as an excellent anti-inflammatory and antioxidant therapeutic agent. This review underscores BCP's immunomodulatory and anti-inflammatory properties, highlighting its therapeutic potential for the management of depression and anxiety.